BeyondSpring Inc.
https://www.beyondspringpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BeyondSpring Inc.
CARSgen Wins China’s Fifth CAR-T Approval But Pricing Dilemma Unresolved
As China’s fifth approved CAR-T cell therapy, CARSgen/Huadong’s zevorcabtagene autoleucel is priced at $159,735 for a single infusion. Expanding patient access will become a formidable task for the companies, due to the poor prospects of reimbursement coverage by China’s public medical insurance program.
GSK’s Blenrep Comeback On The Cards After Second Trial Win
The DREAMM-8 study was unblinded early thanks to strong interim results, giving Blenrep a shot at returning as a second-line or later treatment for multiple myeloma
Gilead Touts Catalyst-Rich 2024 Amid Sales Slump
The drug maker pointed to a variety of key trial readouts over the course of the year, including the pivotal study of its long-acting HIV PrEP injectable and Phase III updates for Trodelvy.
Focus On Execution Pays Off Across Bristol’s New Product Portfolio
BMS reiterated its 2024 focus on execution across its portfolio and R&D pipeline as it works through upcoming losses of exclusivity, and its fourth quarter revenues reflected year-end efforts to drive sales.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Dalian Wanchunbulin Pharmaceuticals Ltd.
- Seed Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice